LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced today that data from three randomized, placebo-controlled Phase 1 clinical trials of PRX-08066, a novel serotonin 5-HT2B receptor antagonist, will be the focus of a poster presentation at the Evolution of Pulmonary Hypertension: Emerging Diseases and Novel Therapeutics meeting at the National Institutes of Health in Bethesda, Maryland on December 7-8, 2006. Data from these trials provide support for the ongoing Phase 2a clinical trial of PRX-08066 in patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD).
